ArticleScientific reports2026
Serum proteomic signatures and an immune-calcium signaling cascade associated with antipsychotic-related erectile dysfunction in schizophrenia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Antipsychotic-related erectile dysfunction (APRED) may represent a clinically significant yet poorly understood biological vulnerability in a subset of male patients with schizophrenia, rather than a simple pharmacological side effect. Identifying molecular mechanisms associated with APRED may facilitate early identification of susceptible individuals and inform precision treatment strategies. In a case-control design, 66 male patients with schizophrenia receiving risperidone monotherapy were stratified into APRED and non-APRED groups based on nocturnal penile tumescence monitoring. Label-free quantitative serum proteomics was performed to identify differentially expressed proteins (DEPs). Multivariate statistical analyses, functional enrichment, and protein-protein interaction (PPI) network analyses were conducted to characterize the molecular landscape associated with APRED. A total of 473 DEPs were identified between the APRED and non-APRED groups, with principal component analysis demonstrating clear group separation. Functional annotation showed significant enrichment of pathways related to immune and inflammatory responses, calcium signaling, and extracellular matrix organization. PPI network analysis of the top 40 DEPs identified 10 hub proteins, including RYR3, PRKCA, and KRT18, with RYR3 emerging as a central regulatory node linking calcium signaling and immune-related pathways. These findings identify a distinct serum proteomic signature associated with APRED in schizophrenia. The results are consistent with a hypothesized cascade characterized by gene expression reprogramming, immune and calcium signaling disruption, and subsequent structural-functional imbalance. Collectively, this study suggests that APRED may represent a peripheral manifestation of a schizophrenia-related biological subtype with intrinsic vulnerability along an immune-calcium signaling axis, providing a potential framework for early risk stratification and precision psychopharmacological management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.